Prevalence and predictive value of intermittent viremia with combination hiv therapy.
暂无分享,去创建一个
M. Hirsch | D. Richman | H. Günthard | D. Havlir | J. Condra | P. Gilbert | J. Wong | C. Ignacio | A. Collier | P. Tebas | R. Bassett | D. Levitan | H F Günthard | J K Wong | D D Richman | D V Havlir | M S Hirsch | P Gilbert | C Ignacio | A C Collier | R Bassett | D Levitan | P Tebas | J Condra | D. Levitan | Roland L. Bassett | M. Hirsch | Peter B. Gilbert
[1] Marilyn M. Wagener,et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection (vol 133, pg 21, 2000) , 2002 .
[2] B. Ledergerber,et al. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. , 1999, AIDS research and human retroviruses.
[3] F. Mammano,et al. Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo , 1998, Journal of Virology.
[4] Susan Swindells,et al. Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.
[5] D. Nixon,et al. Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. , 2000, The Journal of infectious diseases.
[6] Z. Grossman,et al. Multiple modes of cellular activation and virus transmission in HIV infection: a role for chronically and latently infected cells in sustaining viral replication. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[7] Julio S. G. Montaner,et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long‐term response to therapy , 1998, AIDS.
[8] P. Grambsch,et al. Proportional hazards tests and diagnostics based on weighted residuals , 1994 .
[9] E. Rosenberg,et al. Antiretroviral resistance during successful therapy of HIV type 1 infection. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[10] C. A. Macken,et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. , 1999, The New England journal of medicine.
[11] J. J. Henning,et al. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.
[12] D. Costagliola,et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor , 2000, AIDS.
[13] B Wise,et al. Antiretroviral therapy in adults. , 1996, Journal of the American Academy of Nurse Practitioners.
[14] M. Carrington,et al. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy , 2000, AIDS.
[15] M A Fischl,et al. Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel , 2000 .
[16] Alan S. Perelson,et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy , 2000, Nature Medicine.
[17] F. Brun-Vézinet,et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. , 1998, The New England journal of medicine.
[18] M. Saag,et al. Predictors of optimal virological response to potent antiretroviral therapy. , 1999, AIDS.
[19] P. Reiss,et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. , 1999, The Journal of infectious diseases.
[20] W. O'brien,et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. , 1995, Blood.
[21] H. Temin,et al. Retrovirus variation and reverse transcription: abnormal strand transfers result in retrovirus genetic variation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[22] J. Ioannidis,et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. , 1998, The New England journal of medicine.
[23] Alan S. Perelson,et al. Evolution of Envelope Sequences of Human Immunodeficiency Virus Type 1 in Cellular Reservoirs in the Setting of Potent Antiviral Therapy , 1999, Journal of Virology.
[24] H. Schuitemaker,et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study , 1998, The Lancet.
[25] T V Perneger,et al. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia , 2000, AIDS.
[26] E A Emini,et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. , 1997, The New England journal of medicine.
[27] P. Harrigan,et al. Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation. , 1999, The Journal of infectious diseases.
[28] Jaap Goudsmit,et al. Ongoing HIV dissemination during HAART , 1999, Nature Medicine.
[29] J. Bilello,et al. Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. , 1998, The Journal of infectious diseases.
[30] J. Leonard,et al. The duration of viral suppression during protease inhibitor therapy for HIV‐1 infection is predicted by plasma HIV‐1 RNA at the nadir , 1998, AIDS.
[31] A. Mocroft,et al. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor , 1998, AIDS.
[32] W. Miller,et al. Detectable HIV-1 RNA at levels below quantifiable limits by amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy. , 1999, AIDS.
[33] J. Coffin,et al. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.
[34] J. Coffin,et al. Genetic diversity and evolution of retroviruses. , 1992, Current topics in microbiology and immunology.
[35] Franqois,et al. Genetic recombination of human immunodeficiency virus , 1989, Journal of virology.
[36] A. Mocroft,et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. , 2000, Archives of internal medicine.
[37] A. Perelson,et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. , 1999, The New England journal of medicine.
[38] R. Pomerantz,et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. , 2001, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.